Previous Close | 44.18 |
1-Year Change | -1.3% |
6-Months Change | -11.23% |
3-Months Change | -12.55% |
Moving Avg (50d) | 44.48 |
Moving Avg (200d) | 47.219 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.19B |
Beta (3-Years) | 1.12 |
Revenue Growth (ttm) | 19.46% |
Net Profit Margin (ttm) | -154.87% |
Return On Assets (ttm) | -51.31% |
EPS (ttm) | -8.97 |
PE Ratio (ttm) | -4.93 |
Dividend Yield | % |
Asset Description: | Ultragenyx Pharmaceutical Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-27 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
45.064 | 46.389 | 47.273 | 48.598 | 50.807 | 53.016 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.